Bruker Announces Management Promotions and Strong Fourth Quarter 2009 Preliminary Operating Results

Announces Management Promotions and Strong Fourth Quarter 2009 Preliminary

BILLERICA, Mass. February 4,

2010 Bruker Corporation (NASDAQ: BRKR) this week made certain management

changes effective, and today announces strong preliminary operating results for

its fourth quarter, which ended on December 31, 2009.

Management Promotions Effective February 2010

As previously announced,

effective February 1st, 2010

William Knight, formerly Bruker s Chief Financial Officer, became the Company s

Chief Operating Officer. Mr. Knight

was succeeded as Chief Financial Officer by Brian Monahan, previously the

Company s Vice President of Finance. In

addition, Drs. Werner Maas and Bernd Gewiese were promoted to

Co-Presidents of Bruker s BioSpin division, also effective as of February 1st, 2010.

Frank Laukien, President

and CEO of Bruker Corporation, commented: Bruker is fortunate to have

outstanding and strongly committed management talent within the Company, and we

are very pleased to develop our organization further with such excellent

internal candidates. On behalf of the

entire Company, I wish Bill, Brian, Werner and Bernd much success in continuing

to drive Bruker as a customer-oriented, innovative provider of high-performance

scientific instruments and analytical solutions.

Fourth Quarter 2009 Preliminary

Operating Highlights

announce its fourth quarter (Q4) of 2009 and full year 2009 financial results

on February 25, 2010. The Company s

preliminary, unaudited operating results for the fourth quarter of 2009 have

significantly exceeded previous expectations.

total Bruker revenue is now estimated to

be greater than $355 million (on January 13, 2010, the Company had

estimated Q4 revenue of greater than $340 million)

the Bruker Scientific Instruments (BSI)

segment expects a GAAP operating margin of greater than 18%

the Bruker Energy & Supercon

Technologies (BEST) segment estimates revenue at greater than $20 million, with

year-over-year growth greater than 75%, and BEST also anticipates a reduced

operating loss year-over-year

The Company s fourth

quarter 2009 financial highlights provided above are preliminary and do not

present all information necessary for an understanding of the Company s 2009

financial position and results of operations.

Moreover, the full year 2009 financial results are currently being

audited by the Company s independent registered public accounting firm. The Company s completion of its 2009

financial statements, and the related audit of these financial statements,

could result in material changes to the preliminary financial results stated

Bruker Corporation is a

leading provider of high-performance scientific instruments and solutions for

molecular and materials research, as well as for industrial and applied

analysis. For more information about Bruker Corporation, please visit

statements contained in this press release that do not describe historical

facts may constitute forward-looking statements as that term is defined in the

Private Securities Litigation Reform Act of 1995. Any forward-looking

statements contained herein are based on current expectations, but are subject

to risks and uncertainties, that could cause actual future results to differ

materially from those projected including, but are not limited to, risks and

uncertainties relating to adverse changes in conditions in the global economy

and volatility in the capital markets, the integration of businesses we have

acquired or may acquire in the future, changing technologies, product

development and market acceptance of our products, the cost and pricing of our

products, manufacturing, competition, dependence on collaborative partners and

key suppliers, capital spending and government funding policies, changes in

governmental regulations, realization of anticipated benefits from economic

stimulus programs, intellectual property rights, litigation, and exposure to

foreign currency fluctuations and other risk factors discussed from time to

time in our filings with the Securities and Exchange Commission. These and

other factors are identified and described in more detail in our filings with

the SEC, including, without limitation, our recent Proxy Statements on Schedule

14A, our annual report on Form 10-K for the year ended December 31,

2008, our most recent quarterly reports on Form 10-Q and our current

reports on Form 8-K. We expressly disclaim any intent or obligation to

update these forward-looking statements other than as required by law.